Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab in systemic sclerosis
NCT05198557Phase 3Active, not recruiting
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Jul 2022
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of inebilizumab in systemic sclerosis (SSc), sponsored by Mitsubishi Tanabe Pharma. Started Jul 2022; status: active, not recruiting.
02
Drugs
inebilizumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT05198557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05198557.